Ron Grunstein News Today

Ron Grunstein, MD, PhD, head of sleep and circadian research, Woolcock Institute of Medical Research, shares findings from a phase 1b study on the use of a novel orexin agonist in patients with narcolepsy type 1.

New analysis from SURMOUNT-1 support the use of GLP-1/GIP agonist tirzepatide to reduce weight in patients with OSA and obesity/overweight.

Alkermes will present new data for its investigational narcolepsy treatment, ALKS 2680, at SLEEP 2024 in Houston.

- Late-Breaking Abstracts Containing Data From the Full Narcolepsy Type 1 Cohort From the ALKS 2680 Phase 1b Study and Vibrance-1 Phase 2 Study Design Accepted for Poster Presentations - -

New insights into REM sleep and our emotions may change the way we treat mental health.

Alkermes plc announced positive results from a phase 1b study evaluating ALKS 2680 for treating narcolepsy type 2 and idiopathic hypersomnia.

After 235 years of white ear-plug decision-making, let’s finally listen to the more than 80 per cent of Indigenous people who are asking for a Voice.

New research outlines how regular sleep, rather than duration of sleep, can be a powerful predictor of quality of life.

New research outlines how regular sleep, rather than duration of sleep, can be a powerful predictor of quality of life.

New research outlines how regular sleep, rather than duration of sleep, can be a powerful predictor of quality of life.